NCT03593447View on ClinicalTrials.gov

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

April 23, 2019

Study Completion Date

February 17, 2020

Conditions
Chronic Hepatics C Virus (HCV) Genotype 1Non-CirrhoticCirrhosisTreatment naïve
Interventions
DRUG

non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin

Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg

DRUG

non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin

Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg

DRUG

non-cirrhotic subjects. low TG-2349+ low DAG181

Group 3: TG-2349 200 mg + DAG181 100 mg

DRUG

non-cirrhotic subjects. high TG-2349+ high DAG181

Group 4: TG-2349 400 mg + DAG181 200 mg

DRUG

cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin

Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg\_

DRUG

cirrhotic subjects. high TG-2349+ high DAG181

Group6: TG-2349 400 mg + DAG181 200 mg

Trial Locations (1)

10004

Peking University Peoples Hospital, Beijing

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

lead

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT03593447 - To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients | Biotech Hunter | Biotech Hunter